Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine
- 1 June 2004
- journal article
- clinical trial
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 109 (6) , 390-392
- https://doi.org/10.1111/j.1600-0404.2004.00259.x
Abstract
Chemokines are involved in the pathogenesis of multiple sclerosis. The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines--interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted). Twenty-five patients with relapsing-remitting multiple sclerosis were treated with 2-chlorodeoxyadenosine (Cladribine), administered subcutaneously in 6 cycles repeated every 5 weeks. IL-8 and RANTES levels were measured by the enzyme-linked immunoassay (ELISA) method in serum and cerebrospinal fluid (CSF) before and after treatment. After Cladribine treatment the levels of IL-8 decreased significantly in CSF only, whereas the RANTES levels decreased significantly both in CSF and serum. Our results suggest that Cladribine therapy might modify the circulating level of RANTES.Keywords
This publication has 8 references indexed in Scilit:
- Expression of chemokine receptors in the different clinical forms of multiple sclerosisMultiple Sclerosis Journal, 2002
- Differential release of β-chemokines in serum and CSF of patients with relapsing-remitting multiple sclerosisActa Neurologica Scandinavica, 2001
- Chemokines and chemokine receptors in the pathogenesis of multiple sclerosisMultiple Sclerosis Journal, 2000
- Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patientsJournal of Clinical Investigation, 1999
- Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis1Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc.1Journal of Neuroimmunology, 1999
- Chemokines — Chemotactic Cytokines That Mediate InflammationNew England Journal of Medicine, 1998
- Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2sThe Journal of Experimental Medicine, 1998
- The Clinical Pharmacokinetics of CladribineClinical Pharmacokinetics, 1997